{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T14:10:59Z","timestamp":1779286259246,"version":"3.51.4"},"reference-count":32,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004374","name":"Chongqing Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004374","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005230","name":"Natural Science Foundation of Chongqing Municipality","doi-asserted-by":"publisher","award":["CSTB2022NSCQ-MSX0987"],"award-info":[{"award-number":["CSTB2022NSCQ-MSX0987"]}],"id":[{"id":"10.13039\/501100005230","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.clinthera.2026.03.013","type":"journal-article","created":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T22:32:09Z","timestamp":1775514729000},"page":"487-494","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Physiologically Based Pharmacokinetic Model for Fluzoparib Among Patients With Renal Impairment"],"prefix":"10.1016","volume":"48","author":[{"given":"Yi","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Song","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiulin","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guoxing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaorong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Rao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xian","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2026.03.013_bib0001","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clinthera.2026.03.013_bib0002","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"395","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2026.03.013_bib0003","first-page":"47","article-title":"Onconephrology: the intersections between the kidney and cancer","volume":"71","author":"Rosner","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clinthera.2026.03.013_bib0004","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1136\/esmoopen-2016-000091","article-title":"Renal insufficiency and cancer treatments","volume":"1","author":"Launay-Vacher","year":"2016","journal-title":"ESMO Open"},{"key":"10.1016\/j.clinthera.2026.03.013_bib0005","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1159\/000323740","article-title":"Chronic kidney disease in cancer patients: an independent predictor of cancer-specific mortality","volume":"33","author":"Na","year":"2011","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.clinthera.2026.03.013_bib0006","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.semnephrol.2010.09.003","article-title":"Epidemiology of chronic kidney disease in cancer patients: lessons from the IRMA study group","volume":"30","author":"Launay-Vacher","year":"2010","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.clinthera.2026.03.013_bib0007","doi-asserted-by":"crossref","first-page":"e200","DOI":"10.1016\/S1470-2045(19)30145-7","article-title":"Dose recommendations for anticancer drugs in patients with renal or hepatic impairment","volume":"20","author":"Krens","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clinthera.2026.03.013_bib0008","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1053\/j.seminoncol.2023.09.005","article-title":"PARP inhibitors: a review of the pharmacology, pharmacokinetics, and pharmacogenetics","volume":"51","author":"Zeng","year":"2024","journal-title":"Semin Oncol"},{"key":"10.1016\/j.clinthera.2026.03.013_bib0009","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s40265-021-01541-x","article-title":"Fluzoparib: first approval","volume":"81","author":"Lee","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2026.03.013_bib0010","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/psp4.12134","article-title":"Applied concepts in PBPK modeling: how to build a PBPK\/PD model","volume":"5","author":"Kuepfer","year":"2016","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.clinthera.2026.03.013_bib0011","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/cpt.2125","article-title":"Physiologically-based pharmacokinetic modeling in renal and hepatic impairment populations: a pharmaceutical industry perspective","volume":"110","author":"Heimbach","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2026.03.013_bib0012","series-title":"Draft Guidance, Pharmacokinetics in Patients with Impaired Renal Function\u2014Study Design, Data Analysis, and Impact on Dosing and Labeling","year":"2020"},{"key":"10.1016\/j.clinthera.2026.03.013_bib0013","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.3390\/pharmaceutics15041250","article-title":"Predicting hydroxychloroquine clearance in healthy and diseased populations using a physiologically based pharmacokinetic approach","volume":"15","author":"Alqahtani","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.clinthera.2026.03.013_bib0014","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.2147\/DDDT.S387920","article-title":"Dose adjustment of poly (ADP\u2011Ribose) polymerase inhibitors in patients with hepatic or renal impairment","volume":"16","author":"Zhao","year":"2022","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.clinthera.2026.03.013_bib0015","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/bdd.2282","article-title":"Physiologically-based pharmacokinetic model for alectinib, ruxolitinib, and panobinostat in the presence of cancer, renal impairment, and hepatic impairment","volume":"42","author":"Alsmadi","year":"2021","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.clinthera.2026.03.013_bib0016","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00280-021-04376-1","article-title":"Effect of fluconazole on the pharmacokinetics of fluzoparib: an open-label, crossover study in Chinese healthy male volunteers","volume":"89","author":"Chen","year":"2022","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clinthera.2026.03.013_bib0017","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1080\/17425255.2021.1881480","article-title":"A phase I study of fluzoparib tablet formulation, an oral PARP inhibitor: effect of food on the pharmacokinetics and metabolism after oral dosing in healthy Chinese volunteers","volume":"17","author":"Wu","year":"2021","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.clinthera.2026.03.013_bib0018","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s00280-023-04536-5","article-title":"Itraconazole interferes in the pharmacokinetics of fuzuloparib in healthy volunteers","volume":"91","author":"Hu","year":"2023","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clinthera.2026.03.013_bib0019","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/bcp.14926","article-title":"The impact of rifampicin on the pharmacokinetics of fluzoparib in healthy Chinese male volunteers","volume":"88","author":"Zhang","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2026.03.013_bib0020","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/s10637-023-01331-0","article-title":"Effect of a moderate CYP3A inducer efavirenz on the pharmacokinetics of fluzoparib: an open-label, fixed sequence study in Chinese healthy male subjects","volume":"41","author":"Hu","year":"2023","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.clinthera.2026.03.013_bib0021","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1007\/s10637-020-01034-w","article-title":"Pharmacokinetic effects of proton pump inhibitors on the novel PARP inhibitor fluzoparib: a single-arm, fixed-sequence trial in male healthy volunteers","volume":"39","author":"Li","year":"2021","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.clinthera.2026.03.013_bib0022","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1111\/bcp.15256","article-title":"Metabolite profiles and mass balance of fluzoparib, a novel poly (ADP-ribose) polymerase inhibitor, in subjects with advanced solid cancers","volume":"88","author":"Bian","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2026.03.013_bib0023","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1002\/jcph.1713","article-title":"A physiological approach to pharmacokinetics in chronic kidney disease","volume":"60","author":"Malik","year":"2020","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2026.03.013_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmd.2025.100042","article-title":"A review of physiologically based pharmacokinetic modeling of renal drug disposition","volume":"53","author":"Huang","year":"2025","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.clinthera.2026.03.013_bib0025","doi-asserted-by":"crossref","first-page":"29302","DOI":"10.1021\/acsomega.3c02673","article-title":"Physiologically based pharmacokinetic model to predict metoprolol disposition in healthy and disease populations","volume":"8","author":"Zamir","year":"2023","journal-title":"ACS Omega"},{"key":"10.1016\/j.clinthera.2026.03.013_bib0026","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3390\/ph17020265","article-title":"A comprehensive physiologically based pharmacokinetic model of nadolol in adults with renal disease and pediatrics with supraventricular tachycardia","volume":"17","author":"Kalsoom","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.clinthera.2026.03.013_bib0027","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.3390\/pharmaceutics15071922","article-title":"Physiologically based pharmacokinetic modelling to predict imatinib exposures in cancer patients with renal dysfunction: a case study","volume":"15","author":"Rowland Yeo","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.clinthera.2026.03.013_bib0028","doi-asserted-by":"crossref","first-page":"370","DOI":"10.21147\/j.issn.1000-9604.2020.03.08","article-title":"Phase I dose-escalation and expansion study of PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumors","volume":"32","author":"Li","year":"2020","journal-title":"Chin J Cancer Res"},{"key":"10.1016\/j.clinthera.2026.03.013_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102139","article-title":"Drug dosing in cancer patients with decreased kidney function: a practical approach","volume":"93","author":"Sprangers","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clinthera.2026.03.013_bib0030","doi-asserted-by":"crossref","first-page":"778","DOI":"10.3390\/pharmaceutics13060778","article-title":"Physiologically based pharmacokinetic modelling of cabozantinib to simulate enterohepatic recirculation, drug-drug interaction with rifampin and liver impairment","volume":"13","author":"Gerner","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.clinthera.2026.03.013_bib0031","article-title":"Application of physiologically based pharmacokinetic modeling to evaluate the drug-drug and drug-disease interactions of apatinib","volume":"12","author":"Liu","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clinthera.2026.03.013_bib0032","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/cpt.1103","article-title":"Physiologically based pharmacokinetic modeling for olaparib dosing recommendations: bridging formulations, drug interactions, and patient populations","volume":"105","author":"Pilla Reddy","year":"2019","journal-title":"Clin Pharmacol Ther"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291826000767?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291826000767?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T13:35:30Z","timestamp":1779284130000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291826000767"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0149291826000767"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.03.013","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Physiologically Based Pharmacokinetic Model for Fluzoparib Among Patients With Renal Impairment","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.03.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}